S
Zodix
Study
Academic Library
Search
Shelves
Open access
Sign in
Search or jump to…
⌘K
Stephen Tully · Study
Home
/
Author
Stephen Tully
1 works
· latest 2019
· 1 institutions
cluster: provisional
Follow
Claim this profile
h-index
1
i10
1
Citations
73
Works here
1
19
Most cited in this library
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis
2019 · 73 citations
Works
1 shown
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis
The Oncologist
·
2019
·
4 authors
·
Open access
73
citations